FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Dicerna Pharmaceuticals, Inc. Enters into a Definitive Agreement to be acquired by Novo Nordisk for USD3.3 Billion”
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) surged over 78% in premarket trading after Novo Nordisk entered into a definitive agreement to acquire the company for roughly 3.3 billion dollars.
Novo Nordisk and Dicerna have been parties to a research collaboration working to discover and develop RNAi therapies since 2019, with the former paying $38.25 per share in cash to acquire Dicerna.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna’s GalXC platform has the potential to address conditions that are difficult to treat with other modalities.
For more information, please visit: Dicerna Pharmaceuticals, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.